Bristol Myers
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis ; pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma ; ipilimumab (Yervoy), to treat cancer ; and luspatercept (Reblozyl) for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States.
Recent news mentioning Bristol Myers
- — Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors
- — Johnson & Johnson (JNJ) Taps Sail Biomedicines in Bid for CAR-T Edge Over Bristol Myers Squibb
- — Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO
- — Hematogenix's MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma
- — Why Novartis, Lilly, and Bristol Myers Are Eyeing This Clinical-Stage Cancer Play
- — Hematogenix's Proprietary MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma
- — Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?
- — Bristol Myers Squibb to build $2.3 billion Houston campus
- — AZN rebounds after report dismisses AstraZeneca-Bristol Myers merger speculation
- — Exclusive-'No discussions' over AstraZeneca-Bristol Myers deal, senior source says
- — Pharmakonzern: Keine Fusionsgespräche zwischen AstraZeneca und Bristol Myers Squibb
- — Best Buy downgraded, Bristol Myers upgraded: Wall Street's top analyst calls